Cardiff Oncology(CRDF) - 2023 Q3 - Earnings Call Presentation

2 Onvansertib's clinical signal of efficacy and tolerability 2. Generate data from the 1* line RAS-mutated mCRC CRDF-004 trial in mid-2024 Preclinical programs indications Cardiff Oncology is focused on three objectives to create value 1. Lead program: RAS-mut mCRC Generate data from the 1*t line RAS-mutated mCRC CRDF-004 trial in mid-2024 1. – Onvansertib and bevacizumab have independent MOAs reducing tumor vasculature – Data from mCRC study in 135 patients identified resistance mechanisms RAS-mut mCRC Onv ...